PMID- 32018220
OWN - NLM
STAT- MEDLINE
DCOM- 20201126
LR  - 20201126
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 125
DP  - 2020 May
TI  - Investigation of protective effects of apilarnil against lipopolysaccharide 
      induced liver injury in rats via TLR 4/ HMGB-1/ NF-kappaB pathway.
PG  - 109967
LID - S0753-3322(20)30157-8 [pii]
LID - 10.1016/j.biopha.2020.109967 [doi]
AB  - Sepsis caused by infection is one of the most important problems of clinical 
      medicine. This study aimed to determine the effect of Apilarnil (API), a bee 
      product, on lipopolysaccharide (LPS) induced liver injury. In the study, 64 adult 
      Sprague-Dawley rats were divided into eight groups; control, 0.2, 0.4 and 0.8 g / 
      kg apilarnil (API) treated groups, LPS (30 mg / kg) group, LPS + 0.2, LPS + 0.4 
      and LPS + 0.8 g / kg API. At tissues obtained from rats, histopathological 
      evaluation, biochemical analysis by ELISA (Catalase-CAT, malondialdehyde-MDA, 
      superoxide dismutase-SOD, xanthine oxidase-XOD, and testican 1-TCN-1), 
      immunohistochemical evaluation (Toll-like receptor 4 (TLR4), High Mobility Group 
      Box Protein 1 (HMGB-1), nuclear factor kappa B (NF-kappaB), Tumor necrosis 
      factor-alpha (TNF-alpha), Interleukin 1 beta (IL-1beta), Interleukin 6 (IL-6) and 
      Inducible nitric oxide (iNOS)), TUNEL analysis to determine the number of 
      apoptotic cells and Comet test as an indicator of DNA damage were performed. 
      Histopathological examination revealed dilated blood vessels, inflammatory cell 
      infiltration, and pyknotic nuclei damaged hepatocytes in the liver tissues of the 
      LPS group. It was found that tissue damage was decreased significantly in 
      LPS + API treatment groups compared to the LPS group. The number of TUNEL 
      positive cells observed in the LPS group in liver samples increased compared to 
      control and API-treated groups only (p < 0.05). The number of TUNEL positive 
      cells showed a statistically significant decrease compared to the LPS group in 
      the groups treated with LPS + API. LPS treatment increased MDA, XOD, and TCN 1 
      levels and decreased SOD and CAT levels; this effect was reversed in the groups 
      treated with LPS + API. In the LPS group, DNA damage was significantly increased 
      when compared with the LPS + API. LPS treatment increased expression of TLR4, 
      HMGB-1, NF-kappaB, iNOS, TNF-alpha, IL-1beta, IL-6; in the groups treated with LPS + API 
      reduced this increase. In conclusion, apilarnil administered in rats may be 
      thought to prevent LPS-induced liver damage by inhibiting the TLR4 / HMGB-1 / 
      NF-kappaB signaling pathway.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Masson SAS.. All rights 
      reserved.
FAU - Doganyigit, Zuleyha
AU  - Doganyigit Z
AD  - Yozgat Bozok University, Faculty of Medicine, Department of Histology and 
      Embryology, Erdogan Akdag Campus, Yozgat, Turkey. Electronic address: 
      zuleyha.doganyigit@yobu.edu.tr.
FAU - Okan, Asli
AU  - Okan A
AD  - Yozgat Bozok University, Faculty of Medicine, Department of Histology and 
      Embryology, Erdogan Akdag Campus, Yozgat, Turkey. Electronic address: 
      oflamaz.asly@gmail.com.
FAU - Kaymak, Emin
AU  - Kaymak E
AD  - Yozgat Bozok University, Faculty of Medicine, Department of Histology and 
      Embryology, Erdogan Akdag Campus, Yozgat, Turkey. Electronic address: 
      e_kaymak@hotmail.com.
FAU - Pandir, Dilek
AU  - Pandir D
AD  - Yozgat Bozok University, Faculty of Arts and Science, Department of Biology, 
      Erdogan Akdag Campus, Yozgat, Turkey. Electronic address: 
      dilek.pandir@yobu.edu.tr.
FAU - Silici, Sibel
AU  - Silici S
AD  - Erciyes University, Seyrani Faculty of Agriculture, Department of Agricultural 
      Biotechnology, Kayseri, Turkey. Electronic address: silicis@erciyes.edu.tr.
LA  - eng
PT  - Journal Article
DEP - 20200202
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Biological Products)
RN  - 0 (HMGB1 Protein)
RN  - 0 (Hbp1 protein, rat)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (NF-kappa B)
RN  - 0 (Tlr4 protein, rat)
RN  - 0 (Toll-Like Receptor 4)
RN  - 0 (apilarnil)
SB  - IM
MH  - Animals
MH  - Biological Products/*therapeutic use
MH  - Chemical and Drug Induced Liver Injury/*prevention & control
MH  - Gene Expression Regulation/drug effects
MH  - HMGB1 Protein/genetics/*metabolism
MH  - Lipopolysaccharides/*toxicity
MH  - NF-kappa B/genetics/*metabolism
MH  - Rats
MH  - Toll-Like Receptor 4/genetics/*metabolism
OTO - NOTNLM
OT  - Apilarnil
OT  - Apoptosis
OT  - Inflammation
OT  - LPS
OT  - Liver
OT  - Oxidative stress
COIS- Declaration of Competing Interest There is no conflict of interest among the 
      authors.
EDAT- 2020/02/06 06:00
MHDA- 2020/11/27 06:00
CRDT- 2020/02/05 06:00
PHST- 2019/12/20 00:00 [received]
PHST- 2020/01/20 00:00 [revised]
PHST- 2020/01/26 00:00 [accepted]
PHST- 2020/02/06 06:00 [pubmed]
PHST- 2020/11/27 06:00 [medline]
PHST- 2020/02/05 06:00 [entrez]
AID - S0753-3322(20)30157-8 [pii]
AID - 10.1016/j.biopha.2020.109967 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2020 May;125:109967. doi: 10.1016/j.biopha.2020.109967. Epub 
      2020 Feb 2.